Combination chemotherapy involving orally administered etoposide and JM-21 6 in murine tumor models

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 51-56

  Rose, William C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Etoposide; JM 216; Therapeutic synergy; VP 16

Indexed keywords

ETOPOSIDE; SATRAPLATIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LEUKEMIA P 388; MORTALITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOMA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; LEUKEMIA P388; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS;

EID: 0030894039     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050624     Document Type: Article

References (18)

1. Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G (1978) Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie 60: 961
2. Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW (1978) VP16-213 monotherapy for remission induction of small-cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62:473
3. Corbett TH, Griswold DP Jr, Wolpert MK, Venditti JM, Schabel FM Jr (1979) Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep 63: 799
4. Gehan EA (1985) A generalized Wilcoxon test for comparing arbitrarily singlycensored samples. Biometrika 52: 203
5. Issell BF, Rudolph AR, Louie AC (1984) Etoposide (VP-16-213): an overview. In: Issell BF, Muggia FM, Carter SK (eds) Etoposide (VP-16): current status and new developments. Academic Press, New York, pp 1-13
6. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer B, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-dichlorocyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53: 2581
7. Mabel JA (1979) Therapeutic synergism in murine tumors for combinations of cis-diamminedichloroplatinum with VP16-213 or BCNU. Am Assoc Cancer Res 20: 230
8. McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynee J, Harrapp KR (1994) Schedule dependency of orally administered bisacetato-ammine-dichlorocyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res 54: 4118
9. McKeage MJ, Raynaud F, Ward J, Berry C, O' Dell D, Misstry P, Kelland LR, Santabarbara P, Harrap KR, Judson IR (1994) Phase I and pharmacokinetic study of an orally administered platinum (Pt) complex (JM216) using a daily Z 5 administration schedule. Proc Am Soc Clin Oncol 13: 136
10. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR, Judson IR (1995) A phase I and Pharmacology study of an oral platinum complex. JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451
11. Nicolson MC, McKeage M, Raynaoud F, Ward J, Berry C, Murrer B, Harrap K, Judson I (1994) A daily Z 5 phase I trial of the oral platinum anticancer drug JM 216 [AF-bis(acetato)-B-ammine-CD-dichloro-e-cyclohexylamine platinum IV]. Br J Cancer 69: 949
12. Rose WC, Crosswell AR, Schurig JE, Casazza AM (1993) Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 32: 197
13. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Mayo JG, Lloyd HH (1979) Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors of man. In: Busch H. DeVita V Jr (eds) Cancer drug development, part B. Methods in cancer research, vol. 17, Academic Press, New York, vol. 17, pp 3-51
14. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr (1979) Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459
15. Skipper HE (1974) Combination therapy: some concepts and results. Cancer Chemother Rep [Part 2] 4: 137
16. Slevin M, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1990) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333
17. Stahelin H (1973) Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer 9: 215
18. Venditti JM, Goldin A (1964) Drug synergism in antineoplastic chemotherapy. In: Goldin A, Hawking F (eds) Advances in chemotherapy, vol. 1 Academic Press, New York, pp 397-498